

| Computation of Ceiling Price based on July, 2022 Data under DPCO, 2013 | | | | | | | | | | | | | | | | | | | |
|--|------------------------|-------------------------|----------------------------------|--------------------|------------------------------|----------|-----------|---------|-----------------------|---|---------------------------|------------------------------------|------------------------------------|-------------------------------|--|--|--|--|--------|
| | 2.1.5 | Paracetamol | Injection 150 mg/ mL P,S,T | Each ML (2ML Pack) | | | | | | Number of Companies consisting of Market Share of 1% & Above | | | | | | | | | 5 |
| | | | | | | | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | | | | | | | 847.05 |
| | | | | | | | | | | Sum of PTR per unit considered for price calculation | | | | | | | | | 15.27 |
| | | | | | | | | | | Number of Packs considered | | | | | | | | | 5 |
| | | | | | | | | | | Average PTR | | | | | | | | | 3.05 |
| | | | | | | | | | | Add : 16% Retailer Margin | | | | | | | | | 0.49 |
| | | | Each pack (2ml) | | Per ML | | | | | Ceiling Price (without GST) | | | | | | | | | 3.54 |
| | | | Ceiling Price w.e.f. 01.04.2023 | 8.02 | 4.01 | | | | | % Reduction with compared to Highest Price | | | | | | | | | 42.59% |
| | | | Maximum Permissible PTR | 6.91 | 3.46 | | | | | Final Ceiling Price (without GST) | | | | | | | | | 3.54 |
| | | | (S.O. 1573(E) dated 31.03.2023) | | | | | | | Add: WPI Increase @ 12.1218% | | | | | | | | | 0.43 |
| | | | | | | | | | | Ceiling Price (without GST) w.e.f. 01.04.2023 or date of notification, whichever is later | | | | | | | | | 3.97 |
| | | | | | | | | | | | | | | | | | | | 2.00 |
| | | | Each pack (2ml) | | | | | | | Minimum Price (Rs.) | | | | | | | | | 5.32 |
| | | | Ceiling Price | 7.16 | | | | | | Maximum Price (Rs.) | | | | | | | | | 3.05 |
| | | | Maximum Permissible PTR | 6.17 | | | | | | Average of all considered (Rs.) | | | | | | | | | 3.97 |
| | | | (S.O. 1499(E) dated 30.03.2022) | | | | | | | Ceiling Price (Rs.) | | | | | | | | | 1.02% |
| | | | | | | | | | | Reduction from current ceiling price | | | | | | | | | |
| S.No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT PTR(Rs.) | 8,53,85,048 Brandwise MAT (Ignoring 0 MAT) | 100% SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | M3 Price per Unit (Rs.) Considered | | | | |
| 1 | 2.1.5 | PARACETAMOL N2B1 | BIOCETAMOL 150 MG INJECTION 2 ML | BIOCETAMOL | ZYDUS CADILA - ZHL | 150mg/ml | 2 | Each ML | 4 | 820 | 0.00% | 0.00% | N | 2.00 | | | | | |
| 2 | | PARACETAMOL N2B1 | PARACAD 150 MG INJECTION 2 ML | PARACAD | ZYDUS CADILA - ZHL | 150mg/ml | 2 | Each ML | 3.96 | 17230 | 0.02% | 0.02% | N | 1.98 | | | | | |
| 3 | | PARACETAMOL N2B3 | FEVASTIN 150 MG INJECTION 2 ML | FEVASTIN | TABLETS INDIA LTD | 150mg/ml | 2 | Each ML | 10.64 | 72651718 | 85.09% | 85.09% | Y | 5.32 | 5.32 | | | | |
| 4 | | PARACETAMOL N2B4 | FEVERYL 150 MG INJECTION 2 ML | FEVERYL | MERCURY HEALTH CARE PVT LTD | 150mg/ml | 2 | Each ML | 5.05 | 653238 | 0.77% | 0.77% | N | 2.53 | | | | | |
| 5 | | PARACETAMOL N2B5 | FEVRIDOL 150 MG INJECTION 2 ML | FEVRIDOL | ZUVENTUS HEALTHCARE LTD | 150mg/ml | 2 | Each ML | 7.53 | 1032 | 0.00% | 0.00% | N | 3.77 | | | | | |
| 6 | | PARACETAMOL N2B6 | FLUMOL 150 MG INJECTION 2 ML | FLUMOL | ELDER PHARMACEUTICALS LTD | 150mg/ml | 2 | Each ML | 2.38 | 52 | 0.00% | 0.00% | N | 1.19 | | | | | |
| 7 | | PARACETAMOL N2B7 | MEDOMOL 150 MG INJECTION 2 ML | MEDOMOL | MEDOPHARM | 150mg/ml | 2 | Each ML | 5.34 | 1083860 | 1.27% | 1.27% | Y | 2.67 | 2.67 | | | | |
| 8 | | PARACETAMOL N2B1 | METACIN 150 MG INJECTION 2 ML | METACIN | THEMIS MEDICARE LTD. | 150mg/ml | 2 | Each ML | 5.17 | 849916 | 1.00% | 1.00% | Y | 2.59 | 2.59 | | | | |
| 9 | | PARACETAMOL N2B1 | MOL 150 MG INJECTION 2 ML | MOL | GUFIC BIOSCIENCE LTD | 150mg/ml | 2 | Each ML | 6 | 6768 | 0.01% | 0.01% | N | 3.00 | | | | | |
| 10 | | PARACETAMOL N2B1 | MYPAR 150 MG INJECTION 2 ML | MYPAR | MOREPEN LABORATORIES LIMITED | 150mg/ml | 2 | Each ML | 2.6 | 1136 | 0.00% | 0.00% | N | 1.30 | | | | | |
| 11 | | PARACETAMOL N2B1 | NEOMOL 150 MG INJECTION 2 ML | NEOMOL | NEON LABORATORIES LTD | 150mg/ml | 2 | Each ML | 5.38 | 6354017 | 7.44% | 7.44% | Y | 2.69 | 2.69 | | | | |
| 12 | | PARACETAMOL N2B1 | PCM 150 MG INJECTION 2 ML | PCM | INTAS PHARMACEUTICALS LTD | 150mg/ml | 2 | Each ML | 4 | 3765261 | 4.41% | 4.41% | Y | 2.00 | 2.00 | | | | |

| Computation of Ceiling Price based on July, 2022 Data under DPCO, 2013 | | | | | | | | | | | | | | | | | | | |
|--|------------------------|-------------------------|--|-----------------------|--|----------|-----------|------|--------------------|---|---------------------|--------------------------------------|--------------------------|-----------------------------|----------------------|----------------------|----------------------|----------------------|--|
| | | | | | | | | | | Number of Companies consisting of Market Share of 1% & Above | | | | | | | | | 1 |
| | 23.1.4 | Risperidone | Injection (Long acting) 25 mg P,S,T | | | per ml | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | | | | | | | 97.31 |
| | | | | | | | | | | Sum of PTR per unit considered for price calculation | | | | | | | | | 1912.51 |
| | | | | | | | | | | Number of Packs considered | | | | | | | | | 1 |
| | | | | | | | | | | Average PTR | | | | | | | | | 1912.51 |
| | | | | | | | | | | Less: Reduction as per monopoly conditions | | | | | | | | | 428.45 |
| | | | | | | | | | | PTR after reduction | | | | | | | | | 1484.06 |
| | | | | | | | | | | Add : 16% Retailer Margin | | | | | | | | | 237.45 |
| | | | New Added | | | | | | | Ceiling Price (without GST) | | | | | | | | | 1721.51 |
| | | | | | | | | | | % Reduction with compared to Highest Price | | | | | | | | | 22.40% |
| | | | | | | | | | | Final Ceiling Price (without GST) | | | | | | | | | 1721.51 |
| | | | | | | | | | | Add: WPI Increase @ 12.1218% | | | | | | | | | 208.68 |
| | | | | | | | | | | Ceiling Price (without GST) w.e.f. 01.04.2023 or date of notification, whichever is later | | | | | | | | | 1930.19 |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | Minimum Price (Rs.) |
| | | | | | | | | | | | | | | | | | | | 1912.51 |
| | | | | | | | | | | | | | | | | | | | Maximum Price (Rs.) |
| | | | | | | | | | | | | | | | | | | | 1912.51 |
| | | | | | | | | | | | | | | | | | | | Average of all considered (Rs.) |
| | | | | | | | | | | | | | | | | | | | 1912.51 |
| | | | | | | | | | | | | | | | | | | | Ceiling Price (Rs.) |
| | | | | | | | | | | | | | | | | | | | 1930.19 |
| | | | | | | | | | | | | | | | | | | | Reduction from current ceiling price |
| | | | | | | | | | | | | | | | | | | | NA |
| A. List of items under consideration | | | | | | | | | | | | | | | | | | | |
| S.No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT PTR(Rs.) | 97,30,851 Brandwise MAT (Ignoring 0 MAT) | 100% SKU wise MAT % | 100% Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | M3 Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) |
| 1 | | RISPERIDONE N5A10 | RISPERDAL CONSTA(J&J) 25 MG INJECTION 2 ML | RISPERDAL CONSTA(J&J) | JANSSEN | 25 MG | 2 | ML | 3825.02 | 9730850.88 | 100.00% | 100.00% | Y | 1912.51 | 1912.51 | 1912.51 | 1912.51 | 1912.51 | 1912.51 |
| B. Computation of Average rate of reduction under Monopoly | | | | | | | | | | | | | | | | | | | |
| | | S.No. | Drug | Strength | Route of Administration / Dosage Form & Packsize/Packing, if any | | | | | | | | | S.O. Number & date | | | | | Reduction with reference to the highest PTR under NLEM, 2015 (%) |
| | | 1 | Risperidone | Tablet1 mg | Tablet | | | | | | | | | S.O.89 (E) dt. 06.01.2023 | | | | | 21.07% |
| | | 2 | Risperidone | Tablet2 mg | Tablet | | | | | | | | | S.O.5938 (E) dt. 19.12.2022 | | | | | 26.70% |
| | | 3 | Risperidone | Tablet4 mg | Tablet | | | | | | | | | S.O.5938 (E) dt. 19.12.2022 | | | | | 40.68% |
| | | 4 | Risperidone | Oralliquid1mg/mL | Syrup | | | | | | | | | S.O.194 (E) dt. 11.01.2023 | | | | | 1.16% |
| | | | | | | | | | | | | | | Average reduction | | | | | 22.40% |

| Computation of Ceiling Price based on July, 2022 Data under DPCO, 2013 | | | | | | | | | | | | | | | | | | | |
|--|-------------------------|-------------------------|--|-----------------------------|--|----------|-----------|-----------|----------|---|----------------|---------------------------------|--------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| | | | | | | | | | | Number of Companies consisting of Market Share of 1% & Above | | | | | | | | | 1 |
| | 23.1.4 | Risperidone | Injection (Long acting) 37.5 mg P,S,T | | per ml | | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | | | | | | | 41.58 |
| | | | | | | | | | | Sum of PTR per unit considered for price calculation | | | | | | | | | 2625.00 |
| | | | | | | | | | | Number of Packs considered | | | | | | | | | 1 |
| | | | | | | | | | | Average PTR | | | | | | | | | 2625.00 |
| | | | | | | | | | | Less: Reduction as per monopoly conditions | | | | | | | | | 588.07 |
| | | | | | | | | | | PTR after reduction | | | | | | | | | 2036.93 |
| | | | | | | | | | | Add : 16% Retailer Margin | | | | | | | | | 325.91 |
| | | | New Added | | | | | | | Ceiling Price (without GST) | | | | | | | | | 2362.84 |
| | | | | | | | | | | % Reduction with compared to Highest Price | | | | | | | | | 22.40% |
| | | | | | | | | | | Final Ceiling Price (without GST) | | | | | | | | | 2362.84 |
| | | | | | | | | | | Add: WPI Increase @ 12.1218% | | | | | | | | | 286.42 |
| | | | | | | | | | | Ceiling Price (without GST) w.e.f. 01.04.2023 or date of notification, whichever is later | | | | | | | | | 2649.26 |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | Minimum Price (Rs.) | | | | | | | | | 2625.00 |
| | | | | | | | | | | Maximum Price (Rs.) | | | | | | | | | 2625.00 |
| | | | | | | | | | | Average of all considered (Rs.) | | | | | | | | | 2625.00 |
| | | | | | | | | | | Ceiling Price (Rs.) | | | | | | | | | 2649.26 |
| | | | | | | | | | | Reduction from current ceiling price | | | | | | | | | NA |
| A. List of items under consideration | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | TOTAL MAT | 41,58,000 | 100% | | | | | | | M3 |
| S.No. | Uniqu e No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | PTR(Rs.) | Brandwise MAT (Ignoring 0 MAT) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) |
| 1 | 23.1.4 | RISPERDAL CONSTA(J&J) | RISPERDAL CONSTA(J&J) 37.5 MG INJECTION 2 ML | RISPERIDONE N5A10 | JANSSEN | 37.5 MG | 2 | INJECTION | 5250 | 4158000 | 100.00% | 100.00% | Y | 2625.00 | 2625.00 | | | | |
| | | | | | | | | | | | | | | | | | | | |
| B. Computation of Average rate of reduction under Monopoly | | | | | | | | | | | | | | | | | | | |
| S.No. | Drug | Strength | Route of Administration / Dosage Form & Packsize/Packing, if any | S.O. Number & date | Reduction with reference to the highest PTR under NLEM, 2015 (%) | | | | | | | | | | | | | | |
| 1 | Risperidone | Tablet1 mg | Tablet | S.O.89 (E) dt. 06.01.2023 | 21.07% | | | | | | | | | | | | | | |
| 2 | Risperidone | Tablet2 mg | Tablet | S.O.5938 (E) dt. 19.12.2022 | 26.70% | | | | | | | | | | | | | | |
| 3 | Risperidone | Tablet4 mg | Tablet | S.O.5938 (E) dt. 19.12.2022 | 40.68% | | | | | | | | | | | | | | |
| 4 | Risperidone | Oralliquid1mg/mL | Syrup | S.O.194 (E) dt. 11.01.2023 | 1.16% | | | | | | | | | | | | | | |
| | | | | Average reduction | 22.40% | | | | | | | | | | | | | | |

| Computation of Ceiling Price based on July, 2022 Data under DPCO, 2013 | | | | | | | | | | | | | | | |
|--|------------------------|-------------------------|---------------------------------------|---------------|--|----------|-----------|------|-----------|---------------------------------|----------------|---------------------------------|--------------------------|----------------------|--|
| | 14.1.5 | Povidone iodine | P,S,T | Solution 4% | Per ml | | | | | | | | | | 1 |
| | | | | | | | | | | | | | | | 161.85 |
| | | | | | | | | | | | | | | | 1.39 |
| | | | | | | | | | | | | | | | 1 |
| | | | | | | | | | | | | | | | 1.39 |
| | | | | | | | | | | | | | | | 0.18 |
| | | | | | | | | | | | | | | | 1.21 |
| | | | | | | | | | | | | | | | 0.19 |
| | | | | | | | | | | | | | | | 1.40 |
| | | | | | | | | | | | | | | | 13.26% |
| | | | | | | | | | | | | | | | 1.40 |
| | | | | | | | | | | | | | | | 0.17 |
| | | | | | | | | | | | | | | | 1.57 |
| | | | | | | | | | | | | | | | 1.39 |
| | | | | | | | | | | | | | | | 1.39 |
| | | | | | | | | | | | | | | | 1.39 |
| | | | | | | | | | | | | | | | 1.57 |
| A. List of items under consideration | | | | | | | | | | | | | | | |
| S.No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT | 1,61,84,506 | 100% | M3 | | | |
| | | | | | | | | | PTR(Rs.) | Brandwise MAT (ignoring 0% MAT) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) Considered |
| 1 | 14.1.5 | POVIDONE IODINE | BETADINE FIRST AID 4 % SOLUTION 50 ML | BETADINE | WIN-MEDICARE PVT. LTD. | 4 % | 50 | ml | 69.6 | 16184506 | 100.00% | 100.00% | Y | 1.39 | 1.39 |
| B. Computation of Average rate of reduction under Monopoly | | | | | | | | | | | | | | | |
| | | S.No. | Drug | Strength | Route of Administration / Dosage Form & Packsize/Packing, if any | | | | | S.O. Number & date | | | | | Reduction with reference to the highest PTR under NLEM, 2015 (%) |
| | | 1 | Povidone iodine | Solution 5% | | | | | | S.O. 879(E) dated 24.02.2023 | | | | | 9.12% |
| | | 2 | Povidone iodine | Solution 7.5% | | | | | | S.O. 879(E) dated 24.02.2023 | | | | | 14.04% |
| | | 3 | Povidone iodine | Solution 10% | | | | | | S.O. 879(E) dated 24.02.2023 | | | | | 16.63% |
| | | | | | | | | | | Average reduction | | | | | 13.26% |

Revised

| Computation of Ceiling Price based on July, 2022 Data under Para 4 of DPCO, 2013 | | | | | | | | | | | | | | | |
|--|------------------------|-------------------------|---|----------------|--------------------------------|----------|-----------|------|----------|---|---------------------|---------------------------------|--------------------------|----------------------|---------------------------------|
| | 6.2.2.8 | Gentamicin | Injection 40 mg/mL P,S,T | | Each ML (2ML Pack) | | | | | Number of Companies consisting of Market Share of 1% & Above | | | | | 2 |
| | | | | | | | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | | | 4,438.39 |
| | | | | | | | | | | Sum of PTR per unit considered for price calculation | | | | | 7.46 |
| | | | | | | | | | | Number of Packs considered | | | | | 2 |
| | | | | | | | | | | Average PTR | | | | | 3.73 |
| | | | Each pack (2ml) | | Per ML | | | | | Add : 16% Retailer Margin | | | | | 0.60 |
| | | | Ceiling Price w.e.f. 01.04.2023 | 10.48 | 5.24 | | | | | Ceiling Price (without GST) | | | | | 4.33 |
| | | | Maximum Permissible PTR | 9.03 | 4.52 | | | | | % Reduction with compared to Highest Price | | | | | 0.00% |
| | | | (S.O. 1573(E) dated 31.03.2023) | | | | | | | Final Ceiling Price (without GST) | | | | | 4.33 |
| | | | | | | | | | | Add: WPI Increase @ 12.1218% | | | | | 0.52 |
| | | | | | | | | | | Ceiling Price (without GST) w.e.f. 01.04.2023 or date of notification, whichever is later | | | | | 4.85 |
| | | | Each pack (2ml) | | | | | | | | | | | | 3.73 |
| | | | Ceiling Price | 9.35 | | | | | | | | | | | 3.73 |
| | | | Maximum Permissible PTR | 8.06 | | | | | | | | | | | 3.73 |
| | | | (S.O. 1499(E) dated 30.03.2022) | | | | | | | | | | | | 4.85 |
| | | | | | | | | | | | | | | | 7.35% |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | TOTAL MAT | 44,81,28,174 | 100% | | M3 | |
| S.No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | PTR(Rs.) | Brandwise MAT (Ignoring 0 MAT) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) Considered |
| 1 | 6.2.2.8 | GENTAMICIN J1K1 | GRACIN 40 MG INJECTION 2 ML | GRACIN | ZYDUS CADILA - ZHL | 40 MG/ml | 2 | ML | 6.78 | 19855 | 0.00% | 0.00% | N | 3.39 | |
| 2 | | GENTAMICIN J1K1 | GARAMYCIN 80 MG INJECTION 2 ML | GARAMYCIN | FULFORD (INDIA) LTD. | 40 MG/ml | 2 | ML | 6.93 | 3222 | 0.00% | 0.00% | N | 3.47 | |
| 3 | | GENTAMICIN J1K1 | GENKA 40 MG INJECTION 2 ML | GENKA | CADILA PHARMACEUTICALS LTD | 40 MG/ml | 2 | ML | 5.25 | 520 | 0.00% | 0.00% | N | 2.63 | |
| 4 | | GENTAMICIN J1K1 | GENTALAB 40 MG INJECTION 2 ML | GENTALAB | LABORATE PHARMACEUTICAL LTD | 40 MG/ml | 2 | ML | 5.82 | 78100 | 0.02% | 0.02% | N | 2.91 | |
| 5 | | GENTAMICIN J1K1 | GENTAMICIN (CADILA) 80 MG INJECTION 2 ML | GENTAMICIN (CA | CADILA PHARMACEUTICALS LTD | 40 MG/ml | 2 | ML | 5.25 | 4373 | 0.00% | 0.00% | N | 2.63 | |
| 6 | | GENTAMICIN J1K1 | GENTAMYCIN (FULFORD) 80 MG INJECTION 2 ML | GENTAMYCIN (FU | FULFORD (INDIA) LTD. | 40 MG/ml | 2 | ML | 4.5 | 4028 | 0.00% | 0.00% | N | 2.25 | |
| 7 | | GENTAMICIN J1K1 | GENTICYN 80 MG INJECTION 2 ML | GENTICYN | ABBOTT HEALTHCARE PVT. LTD | 40 MG/ml | 2 | ML | 7.46 | 426098331 | 95.08% | 95.08% | Y | 3.73 | 3.73 |
| 8 | | GENTAMICIN J1K1 | GMI 80 MG INJECTION 2 ML | GMI | RAVIAN PHARMACEUTICALS PVT LTD | 40 MG/ml | 2 | ML | 3.96 | 1635 | 0.00% | 0.00% | N | 1.98 | |
| 9 | | GENTAMICIN J1K1 | MERIGENTA 80 MG INJECTION 2 ML | MERIGENTA | MERCURY HEALTH CARE PVT LTD | 40 MG/ml | 2 | ML | 7.09 | 4028243 | 0.90% | 0.90% | N | 3.55 | |
| 10 | | GENTAMICIN J1K1 | RANBIOTIC 40 MG INJECTION 2 ML | RANBIOTIC | RANBAXY LABORATORIES LTD | 40 MG/ml | 2 | ML | 7.5 | 148857 | 0.03% | 0.03% | N | 3.75 | |
| 11 | | GENTAMICIN J1K1 | BIOGARACIN 80 MG INJECTION 2 ML | BIOGARACIN | ZYDUS CADILA - ZHL | 40 MG/ml | 2 | ML | 7.45 | 17741009 | 3.96% | 3.96% | Y | 3.73 | 3.73 |

Note: Earlier under NLEM, 2015 prices were fixed for pack basis, now changed to each ml basis.

| Computation of Ceiling Price based on July, 2022 Data under DPCO, 2013 | | | | | | | | | | | | | | | | |
|--|------------------------|-------------------------------|--|---------------|--|---|-----------|------|-----------|--------------------------------|----------------|---------------------------------|--------------------------|----------------------|---------------------------------|--------|
| | 19.3.5 | Japanese encephalitis vaccine | As Licensed (4 mcg to 6 mcg) | Each Vial | Number of Companies consisting of Market Share of 1% & Above | | | | | | | | | | 3 | |
| | | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | | | | | | | | 170.74 | |
| | | | P,S,T | | Sum of PTR per unit considered for price calculation | | | | | | | | | | 1561.86 | |
| | | | | | Number of Packs considered | | | | | | | | | | 3 | |
| | | | Ceiling Price w.e.f. 01.04.2023 | 868.40 | Each Pack | Average PTR | | | | | | | | | | 520.62 |
| | | | Maximum Permissible PTR (S.O. 1573(E) dated 31.03.2023) | 748.62 | | Add : 16% Retailer Margin | | | | | | | | | | 83.30 |
| | | | | | | Ceiling Price (without GST) | | | | | | | | | | 603.92 |
| | | | | | | % Reduction with compared to Highest Price | | | | | | | | | | 10.89% |
| | | | Ceiling Price | 774.52 | Each Pack | Final Ceiling Price (without GST) | | | | | | | | | | 603.92 |
| | | | Maximum Permissible PTR (S.O. 1499(E) dated 30.03.2022) | 667.69 | | Add: WPI Increase @ 12.1218% | | | | | | | | | | 73.21 |
| | | | | | | Ceiling Price (without GST) w.e.f. 01.04.2023 or date of notification, whichever is later | | | | | | | | | | 677.13 |
| | | | | | | Minimum Price (Rs.) | | | | | | | | | | 455.73 |
| | | | | | | Maximum Price (Rs.) | | | | | | | | | | 584.23 |
| | | | | | | Average of all considered (Rs.) | | | | | | | | | | 520.62 |
| | | | | | | Ceiling Price (Rs.) | | | | | | | | | | 677.13 |
| A. List of items under consideration | | | | | | | | | | | | | | | | |
| | | | | | | | | | TOTAL MAT | 1,70,73,796 | 100% | | | M3 | | |
| S.No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | PTR(Rs.) | Brandwise MAT (Ignoring 0 MAT) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) Considered | |
| 1 | | ALL OTHER VA | JENVAC INJECTION 0.5 ML | JENVAC | BHARAT BIO TECH INTERNATIONAL | | 1 | Vial | 455.73 | 13287961.04 | 77.83% | 77.83% | Y | 455.73 | 455.73 | |
| 2 | | ALL OTHER VA | JESHIELD INJECTION 0.5 ML | JESHIELD | ABBOTT INDIA LTD. | | 1 | Vial | 521.9 | 2878800.4 | 16.86% | 16.86% | Y | 521.90 | 521.90 | |
| 3 | | ALL OTHER VA | JEEV 6 MCG INJECTION 0.5 ML | JEEV | BIOLOGICAL E LTD | | 1 | Vial | 584.23 | 907034.37 | 5.31% | 5.31% | Y | 584.23 | 584.23 | |

| Computation of Ceiling Price based on July, 2022 Data under DPCO, 2013 | | | | | | | | | | | | | | | | | | |
|--|------------------------|-------------------------|--|---------------|-------------------------------------|----------|-----------|----------------------------|--|---|------------------|---------------------------------|--------------------------------|----------------------|---------------------------------|--|--|--------|
| | | | | | | | | | | Number of Companies consisting of Market Share of 1% & Above | | | | | | | | 1 |
| | 18.4.1 | Clomiphene citrate | Capsule 100 mg | per Capsule | | | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | | | | | | 69.93 |
| | | | T | | | | | | | Sum of PTR per unit considered for price calculation | | | | | | | | 42.86 |
| | | | | | | | | | | Number of Packs considered | | | | | | | | 1 |
| | | | | | | | | | | Average PTR | | | | | | | | 42.86 |
| | | | | | | | | | | Less: Reduction as per monopoly conditions | | | | | | | | 3.54 |
| | | | | | | | | | | PTR after reduction | | | | | | | | 39.32 |
| | | | Ceiling Price w.e.f. 01.04.2023 | 69.3 | Per Capsule | | | | | Add : 16% Retailer Margin | | | | | | | | 6.29 |
| | | | Maximum Permissible PTR | 59.74 | | | | | | Ceiling Price (without GST) | | | | | | | | 45.61 |
| | | | (S.O. 1573(E) dated 31.03.2023) | | | | | | | % Reduction with compared to Highest Price | | | | | | | | 8.25% |
| | | | Ceiling Price | 61.81 | Per Capsule | | | | | Final Ceiling Price (without GST) | | | | | | | | 45.61 |
| | | | Maximum Permissible PTR | 53.28 | | | | | | Add: WPI Increase @ 12.1218% | | | | | | | | 5.53 |
| | | | (S.O. 1499(E) dated 30.03.2022) | | | | | | | Ceiling Price (without GST) w.e.f. 01.04.2023 or date of notification, whichever is later | | | | | | | | 51.14 |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | 42.86 |
| | | | | | | | | | | | | | | | | | | 42.86 |
| | | | | | | | | | | | | | | | | | | 42.86 |
| | | | | | | | | | | | | | | | | | | 51.14 |
| | | | | | | | | | | | | | | | | | | 26.21% |
| | | | | | | | | | | | | | | | | | | |
| A. List of items under consideration | | | | | | | | | | TOTAL MAT | 69,92,977 | 100% | M3 | | | | | |
| S.No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छापा BRAND | कंपनी Company | Strength | Pack Size | Unit | PTR.(Rs.) | Brandwise MAT (Ignoring 0 MAT) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) Considered | | | |
| 1 | 18.4.1 | CLOMIFENE G3G2 | UBIPHENE C 100 MG CAPSULE 10 | UBIPHENE C | FOURRTS INDIA LABORATORIES PVT. LTD | 100 MG | 10 | CAPSULE | 428.57 | 6992977 | 100.00% | 100.00% | Y | 42.86 | 42.86 | | | |
| B. Computation of Average rate of reduction under Monopoly | | | | | | | | | | | | | | | | | | |
| S.No. | Drug | Strength | Route of Administration / Dosage Form & Packsize/Packing, if any | | | | | S.O. Number & date | Reduction with reference to the highest PTR under NLEM, 2015 (%) | | | | | | | | | |
| 1 | Clomiphene citrate | Tablet 50mg | Tablet | | | | | S.O.194 (E) dt. 11.01.2023 | 8.12% | | | | | | | | | |
| 2 | Clomiphene citrate | Tablet 100mg | Tablet | | | | | S.O.194 (E) dt. 11.01.2023 | 5.91% | | | | | | | | | |
| 3 | Clomiphene citrate | Capsule 50mg | Capsule | | | | | Uploaded with current | 10.73% | | | | | | | | | |
| | | | | | | | | Average reduction | 8.25% | | | | | | | | | |

| Computation of Ceiling Price based on July, 2022 Data under DPCO, 2013 | | | | | | | | | | | | | | | |
|--|-------------------------------|----------------------------------|-----------------------------------|------------------|----------------------------|-----------------|------------------|-------------|---------------------------|---|-----------------------|--|---------------------------------|-----------------------------|--|
| | 6.2.2.8 | Gentamicin | Injection 40 mg/mL P,S,T | | Each ML (upto 1.5ml Pack) | | | | | Number of Companies consisting of Market Share of 1% & Above | | | | 1 | |
| | | | | | | | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | | 25.98 | |
| | | | | | | | | | | Sum of PTR per unit considered for price calculation | | | | 2.23 | |
| | | | | | | | | | | Number of Packs considered | | | | 1 | |
| | | | | | | | | | | Average PTR | | | | 2.23 | |
| | | | | | | | | | | Add : 16% Retailer Margin | | | | 0.36 | |
| | | | Not fixed Earlier | | | | | | | Ceiling Price (without GST) | | | | 2.59 | |
| | | | | | | | | | | % Reduction with compared to Highest Price | | | | 0.00% | |
| | | | | | | | | | | Final Ceiling Price (without GST) | | | | 2.59 | |
| | | | | | | | | | | Add: WPI Increase @ 12.1218% | | | | 0.31 | |
| | | | | | | | | | | Ceiling Price (without GST) w.e.f. 01.04.2023 or date of notification, whichever is later | | | | 2.90 | |
| | | | | | | | | | | | | Minimum Price (Rs.) | | 2.23 | |
| | | | | | | | | | | | | Maximum Price (Rs.) | | 2.23 | |
| | | | | | | | | | | | | Average of all considered (Rs.) | | 2.23 | |
| | | | | | | | | | | | | Ceiling Price (Rs.) | | 2.90 | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | TOTAL MAT | 26,23,682 | 100% | | M3 | |
| S.No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT PTR(Rs.) | Brandwise MAT (Ignoring 0 MAT) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) Considered |
| 1 | GENTAMICIN J1K1 | GARAMYCIN 60 MG INJECTION 1.5 ML | GARAMYCIN 60 MG INJECTION 1.5 ML | GARAMYCIN | FULFORD (INDIA) LTD. | 40 MG/ml | 1.5 | ML | 3.01 | 25955 | 0.99% | 0.99% | N | 2.01 | |
| 2 | GENTAMICIN J1K1 | GENTICYN 60 MG INJECTION 1.5 ML | GENTICYN 60 MG INJECTION 1.5 ML | GENTICYN | ABBOTT HEALTHCARE PVT. LTD | 40 MG/ml | 1.5 | ML | 3.34 | 2597726 | 99.01% | 99.01% | Y | 2.23 | 2.23 |

Note: Earlier under NLEM, 2015 prices were fixed for pack basis, now changed to each ml basis.

| Computation of Ceiling Price based on July, 2022 Data under DPCO, 2013 | | | | | | | | | | | | | | | | | |
|--|-----------------------------|-------------------------|-------------------------------|-------------------|---------------------|----------|-----------|------|----------|-----------------------------------|---|--|--------------------------------|----------------------------|------------------------------------|--|-------|
| | | | | | | | | | | | Number of Companies consisting of Market Share of 1% & Above | | | | | | 1 |
| | 7.4.3 & 18.1.1 & 27.1 | Dexamethasone | P,S,T | Injection 4 mg/mL | Each ML (5 ml pack) | | | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | | | | 61.87 |
| | | | | | | | | | | | Sum of PTR per unit considered for price calculation | | | | | | 1.97 |
| | | | | | | | | | | | Number of Packs considered | | | | | | 1 |
| | | | | | | | | | | | Average PTR | | | | | | 1.97 |
| | | | | | | | | | | | Add : 16% Retailer Margin | | | | | | 0.32 |
| | | | Not fixed earlier | | | | | | | | Ceiling Price (without GST) | | | | | | 2.29 |
| | | | | | | | | | | | % Reduction with compared to Highest Price | | | | | | 0.00% |
| | | | | | | | | | | | Final Ceiling Price (without GST) | | | | | | 2.29 |
| | | | | | | | | | | | Add: WPI Increase @ 12.1218% | | | | | | 0.28 |
| | | | | | | | | | | | Ceiling Price (without GST) w.e.f. 01.04.2023 or date of notification, whichever is later | | | | | | 2.57 |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | 1.97 |
| | | | | | | | | | | | | | | | | | 1.97 |
| | | | | | | | | | | | | | | | | | 1.97 |
| | | | | | | | | | | | | | | | | | 2.57 |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | TOTAL MAT | 61,87,446 | 100% | | | | M3 |
| S.No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | PTR(Rs.) | Brandwise MAT (Ignoring 0 MAT) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) Considered | | |
| 1 | | DEXAMETHASONE H2A6 | DEXONA 4 MG INJECTION 5 ML | DEXONA | ZYDUS CADILA - ZHL | 4 MG | 5 | ML | 9.86 | 6187446 | 100.00% | 100.00% | Y | 1.97 | 1.97 | | |

| Computation of Ceiling Price based on July, 2022 Data under DPCO, 2013 | | | | | | | | | | | | | | | | | | |
|--|------------------------|-------------------------|----------------------------------|-----------------------|---------------------------|----------|-----------|---------|--------------------|-------------|------|----|---|----------------|---------------------------------|--------------------------|----------------------|---------------------------------|
| | 2.1.5 | Paracetamol | Injection 150 mg/ mL | Each ML (100 ML Pack) | | | | | | | | | Number of Companies consisting of Market Share of 1% & Above | | | 2 | | |
| | | | P,S,T | | | | | | | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | 307.72 | | |
| | | | | | | | | | | | | | Sum of PTR per unit considered for price calculation | | | 2.46 | | |
| | | | | | | | | | | | | | Number of Packs considered | | | 2 | | |
| | | | | | | | | | | | | | Average PTR | | | 1.23 | | |
| | | | Not Fixed Earlier | | | | | | | | | | Add : 16% Retailer Margin | | | 0.20 | | |
| | | | | | | | | | | | | | Ceiling Price (without GST) | | | 1.43 | | |
| | | | | | | | | | | | | | % Reduction with compared to Highest Price | | | 42.25% | | |
| | | | | | | | | | | | | | Final Ceiling Price (without GST) | | | 1.43 | | |
| | | | | | | | | | | | | | Add: WPI Increase @ 12.1218% | | | 0.17 | | |
| | | | | | | | | | | | | | Ceiling Price (without GST) w.e.f. 01.04.2023 or date of notification, whichever is later | | | 1.60 | | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | Minimum Price (Rs.) | | | 0.33 | | |
| | | | | | | | | | | | | | Maximum Price (Rs.) | | | 2.13 | | |
| | | | | | | | | | | | | | Average of all considered (Rs.) | | | 1.23 | | |
| | | | | | | | | | | | | | Ceiling Price (Rs.) | | | 1.60 | | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| S.No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT PTR(Rs.) | 3,07,71,525 | 100% | M3 | Brandwise MAT (Ignoring 0 MAT) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) Considered |
| 1 | | PARACETAMOL N2B2 | FEVASTIN 150 MG INJECTION 100 ML | FEVASTIN | TABLETS INDIA LTD | 150mg/ml | 100 | Each ML | 212.86 | | | | 29688400 | 96.48% | 96.48% | Y | 2.13 | 2.13 |
| 2 | | PARACETAMOL N2B1 | PCM 150 MG INJECTION 100 ML | PCM | INTAS PHARMACEUTICALS LTD | 150mg/ml | 100 | Each ML | 33.15 | | | | 1083126 | 3.52% | 3.52% | Y | 0.33 | 0.33 |

| Computation of Ceiling Price based on July, 2022 Data under DPCO, 2013 | | | | | | | | | | | | | | | |
|--|------------------------|--|--|-----------------------------|--|----------|-----------|---------|-----------------------|-----------------------------------|-------------------|--|--------------------------------|-------------------------|------------------------------------|
| | | | | | | | | | | | | | | | 1 |
| 6.2.2.1 | Azithromycin | Capsule 500mg | Per Capsule | | | | | | | | | | | | 11.82 |
| | | P,S,T | | | | | | | | | | | | | 15.87 |
| | | | | | | | | | | | | | | | 1 |
| | | | Per capsule | | | | | | | | | | | | 15.87 |
| | | | | | | | | | | | | | | | 1.24 |
| | | Ceiling Price w.e.f. 01.04.2023 | 20.64 | | | | | | | | | | | | 14.63 |
| | | Maximum Permissible PTR | 17.79 | | | | | | | | | | | | 2.34 |
| | | (S.O. 1573(E) dated 31.03.2023) | | | | | | | | | | | | | 16.97 |
| | | | | | | | | | | | | | | | 7.82% |
| | | | | | | | | | | | | | | | 16.97 |
| | | Ceiling Price | 18.41 | | | | | | | | | | | | 2.06 |
| | | Maximum Permissible PTR | 15.87 | | | | | | | | | | | | 19.03 |
| | | (S.O. 1499(E) dated 30.03.2022) | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | 15.87 |
| | | | | | | | | | | | | | | | 15.87 |
| | | | | | | | | | | | | | | | 15.87 |
| | | | | | | | | | | | | | | | 19.03 |
| | | | | | | | | | | | | | | | 7.81% |
| | | | | | | | | | | | | | | | |
| A. List of items under consideration | | | | | | | | | | 11,81,641 | 100% | M3 | | | |
| S.No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT PTR(Rs.) | Brandwise MAT (Ignoring 0 MAT) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) Considered |
| 1 | 6.2.2.1 | AZITHROMYCIN | ARGEX 500 MG CAPSULE 3 | ARGEX | DR. JOHNS LAB | 500 MG | 3 | CAPSULE | 70.34 | 1181500.98 | 99.99% | 99.99% | Y | 23.45 | 15.87 |
| 2 | 6.2.2.1 | AZITHROMYCIN | AZISOFT (GODDRES) 500 MG CAPSULE 3 | AZISOFT (GODDRES) | GODDRES PHAR | 500 MG | 3 | CAPSULE | 70.1 | 140.2 | 0.01% | 0.01% | N | 23.37 | |
| B. Computation of Average rate of reduction under Monopoly | | | | | | | | | | | | | | | |
| S.No. | Drug | Strength | Route of Administration / Dosage Form & Packsize/Packaging, if any | S.O. Number & date | Reduction with reference to the highest PTR under NLEM, 2015 (%) | | | | | | | | | | |
| 1 | Azithromycin | Oral liquid 200 mg/5 mL (p) | Oral Liquid | S.O.484 (E) dt. 02.02.2023 | 10.90% | | | | | | | | | | |
| 2 | Azithromycin | Tablet250mg | Tablet | S.O.484 (E) dt. 02.02.2023 | 6.54% | | | | | | | | | | |
| 3 | Azithromycin | Tablet500mg | Tablet | S.O.484 (E) dt. 02.02.2023 | 4.18% | | | | | | | | | | |
| 4 | Azithromycin | Capsule250mg | Capsule | S.O.1577 (E) dt. 31.03.2023 | 3.09% | | | | | | | | | | |
| 5 | Azithromycin | Tablet 1000mg | Tablet | S.O.1578 (E) dt. 31.03.2023 | 14.40% | | | | | | | | | | |
| 6 | Azithromycin | Powder for Injection 500mg | Injection | S.O.194 (E) dt. 11.01.2023 | 7.83% | | | | | | | | | | |
| | | | | Average reduction | 7.82% | | | | | | | | | | |

| Computation of Ceiling Price based on July, 2022 Data under DPCO, 2013 | | | | | | | | | | | | | | | | | | |
|--|------------------------|-------------------------|--|--------------|--------------------|----------|----------------------------|--|-----------|---|-----------------|---------------------------------|--------------------------------|----------------------|---------------------------------|--|--|--------|
| | | | | | | | | | | Number of Companies consisting of Market Share of 1% & Above | | | | | | | | 1 |
| | 6.7.2.1 | Efavirenz | Capsule 200 mg | per Capsule | | | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | | | | | | 4.01 |
| | | | S,T | | | | | | | Sum of PTR per unit considered for price calculation | | | | | | | | 17.73 |
| | | | | | | | | | | Number of Packs considered | | | | | | | | 1 |
| | | | | | | | | | | Average PTR | | | | | | | | 17.73 |
| | | | | | | | | | | Less: Reduction as per monopoly conditions | | | | | | | | 0.83 |
| | | | | | | | | | | PTR after reduction | | | | | | | | 16.90 |
| | | | Ceiling Price w.e.f. 01.04.2023 | 29.97 | Per Capsule | | | | | Add : 16% Retailer Margin | | | | | | | | 2.70 |
| | | | Maximum Permissible PTR | 25.84 | | | | | | Ceiling Price (without GST) | | | | | | | | 19.60 |
| | | | (S.O. 1573(E) dated 31.03.2023) | | | | | | | % Reduction with compared to Highest Price | | | | | | | | 4.69% |
| | | | Ceiling Price | 26.73 | Per Capsule | | | | | Final Ceiling Price (without GST) | | | | | | | | 19.60 |
| | | | Maximum Permissible PTR | 23.04 | | | | | | Add: WPI Increase @ 12.1218% | | | | | | | | 2.38 |
| | | | (S.O. 1499(E) dated 30.03.2022) | | | | | | | Ceiling Price (without GST) w.e.f. 01.04.2023 or date of notification, whichever is later | | | | | | | | 21.98 |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | 17.73 |
| | | | | | | | | | | | | | | | | | | 17.73 |
| | | | | | | | | | | | | | | | | | | 17.73 |
| | | | | | | | | | | | | | | | | | | 21.98 |
| | | | | | | | | | | | | | | | | | | 26.67% |
| | | | | | | | | | | | | | | | | | | |
| A. List of items under consideration | | | | | | | | | | TOTAL MAT | 4,00,581 | 100% | M3 | | | | | |
| S.No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | PTR.(Rs.) | Brandwise MAT (Ignoring 0 MAT) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) Considered | | | |
| 1 | 18.4.1 | EFAVIRENZ JSB6 | EFAVIR 200 MG CAPSULE 30 | EFAVIR | CIPLA LTD. | 200 MG | 30 | CAPSULE | 531.98 | 400581 | 100.00% | 100.00% | Y | 17.73 | 17.73 | | | |
| B. Computation of Average rate of reduction under Monopoly | | | | | | | | | | | | | | | | | | |
| S.No. | Drug | Strength | Route of Administration / Dosage Form & Packsize/Packing, if any | | | | S.O. Number & date | Reduction with reference to the highest PTR under NLEM, 2015 (%) | | | | | | | | | | |
| 1 | Efavirenz | Tablet 600 mg | Tablet | | | | S.O.194 (E) dt. 11.01.2023 | 4.69% | | | | | | | | | | |
| | | | | | | | Average reduction | 4.69% | | | | | | | | | | |

| Computation of Ceiling Price based on July, 2022 Data under DPCO, 2013 | | | | | | | | | | | | | | | | | | | |
|--|------------------------|-------------------------|------------------------------------|--------------|----------------------------|----------|-----------|--------|----------|---|-------------------|--|--------------------------------|----------------------------|---------------------------------------|--|--|--|--------|
| | | | | | | | | | | Number of Companies consisting of Market Share of 1% & Above | | | | | | | | | 4 |
| | 23.2.1.3 & 23.4.2 | Fluoxetine | Tablet 10 mg | | per Tablet | | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | | | | | | | 24.93 |
| | | | P,S,T | | | | | | | Sum of PTR per unit considered for price calculation | | | | | | | | | 8.55 |
| | | | | | | | | | | Number of Packs considered | | | | | | | | | 4 |
| | | | | | | | | | | Average PTR | | | | | | | | | 2.14 |
| | | | | | | | | | | Add : 16% Retailer Margin | | | | | | | | | 0.34 |
| | | | | | | | | | | Ceiling Price (without GST) | | | | | | | | | 2.48 |
| | | | | | | | | | | % Reduction with compared to Highest Price | | | | | | | | | 10.56% |
| | | | | | | | | | | Final Ceiling Price (without GST) | | | | | | | | | 2.48 |
| | | | | | | | | | | Add: WPI Increase @ 12.1218% | | | | | | | | | 0.30 |
| | | | | | | | | | | Ceiling Price (without GST) w.e.f. 01.04.2023 or date of notification, whichever is later | | | | | | | | | 2.78 |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | 2.00 |
| | | | | | | | | | | | | | | | | | | | 2.39 |
| | | | | | | | | | | | | | | | | | | | 2.14 |
| | | | | | | | | | | | | | | | | | | | 2.78 |
| | | | | | | | | | | | | | | | | | | | 10.30% |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | TOTAL MAT | 25,00,377 | 100% | | | | | | | M3 |
| S.No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | PTR(Rs.) | Brandwise MAT (Ignoring 0% MAT) | SKU wise MAT % | Brandwise e MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) Considered | | | | |
| 1 | 23.2.1.3 | FLUOXETINE N6A8 | CYCLOTIN 10 MG TABLET 15 | CYCLOTIN | ALTEUS BIOGENICS PVT.LTD. | 10 MG | 10 | TABLET | 29.44 | 192808 | 7.71% | 7.71% | Y | 2.94 | 2.39 | | | | |
| 2 | & 23.4.2 | FLUOXETINE N6A8 | F TIN 10 MG TABLET 10 | F TIN | A.N.PHARMACIA | 10 MG | 10 | TABLET | 20 | 564985 | 22.60% | 22.60% | Y | 2.00 | 2.00 | | | | |
| 3 | | FLUOXETINE N6A8 | FLOATIN 10 MG TABLET 10 | FLOATIN | ICON LIFESCIENCES | 10 MG | 10 | TABLET | 21.6 | 1236815 | 49.47% | 49.47% | Y | 2.16 | 2.16 | | | | |
| 4 | | FLUOXETINE N6A8 | FLUDEP (EAST WEST) 10 MG TABLET 10 | FLUDEP (EAS) | EAST WEST PHARMA | 10 MG | 10 | TABLET | 15 | 3990 | 0.16% | 0.16% | N | 1.50 | | | | | |
| 5 | | FLUOXETINE N6A8 | FLUOXET 10 MG TABLET 10 | FLUOXET | SIGMUND PROMEDICA | 10 MG | 10 | TABLET | 19.64 | 3317 | 0.13% | 0.13% | N | 1.96 | | | | | |
| 6 | | FLUOXETINE N6A8 | TRITIN 10 MG TABLET 10 | TRITIN | TRIPADA HEALTHCARE PVT LTD | 10 MG | 10 | TABLET | 20 | 498462 | 19.94% | 19.94% | Y | 2.00 | 2.00 | | | | |

Note: The PTR of item at S.N. 14 is higher than the Maximum Permissible PTR, therefore restricted to Maximum Permissible PTR.

| Computation of Ceiling Price based on July, 2022 Data under DPCO, 2013 | | | | | | | | | | | | | | | | | | | |
|--|------------------------|-------------------------|-------------------------------|--------------|----------------------------|------------|-----------|--------|----------|---|----------------|---------------------------------|--------------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|--------------------------------------|
| | | | | | | | | | | Number of Companies consisting of Market Share of 1% & Above | | | | | | | | | 7 |
| | 23.2.1.3 & 23.4.2 | Fluoxetine | Tablet 40 mg | | | per Tablet | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | | | | | | | 99.63 |
| | | | P,S,T | | | | | | | Sum of PTR per unit considered for price calculation | | | | | | | | | 29.93 |
| | | | | | | | | | | Number of Packs considered | | | | | | | | | 7 |
| | | | | | | | | | | Average PTR | | | | | | | | | 4.28 |
| | | | | | | | | | | Add : 16% Retailer Margin | | | | | | | | | 0.68 |
| | | | | | | | | | | Ceiling Price w.e.f. 01.04.2022 | 6.64 | | | | | | | | per Tablet |
| | | | | | | | | | | Ceiling Price (without GST) | | | | | | | | | 4.96 |
| | | | | | | | | | | % Reduction with compared to Highest Price | | | | | | | | | 9.22% |
| | | | | | | | | | | (S.O. 1573(E) dated 31.03.2023) | | | | | | | | | Final Ceiling Price (without GST) |
| | | | | | | | | | | Add: WPI Increase @ 12.1218% | | | | | | | | | 4.96 |
| | | | | | | | | | | Ceiling Price | 5.93 | | | | | | | | per Tablet |
| | | | | | | | | | | Ceiling Price (without GST) w.e.f. 01.04.2023 or date of notification, whichever is later | | | | | | | | | 5.56 |
| | | | | | | | | | | Maximum Permissible PT | 5.11 | | | | | | | | |
| | | | | | | | | | | (S.O. 1499(E) dated 30.03.2022) | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | Minimum Price (Rs.) |
| | | | | | | | | | | | | | | | | | | | 4.07 |
| | | | | | | | | | | | | | | | | | | | Maximum Price (Rs.) |
| | | | | | | | | | | | | | | | | | | | 4.71 |
| | | | | | | | | | | | | | | | | | | | Average of all considered (Rs.) |
| | | | | | | | | | | | | | | | | | | | 4.28 |
| | | | | | | | | | | | | | | | | | | | Ceiling Price (Rs.) |
| | | | | | | | | | | | | | | | | | | | 5.56 |
| | | | | | | | | | | | | | | | | | | | Reduction from current ceiling price |
| | | | | | | | | | | | | | | | | | | | 16.25% |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | TOTAL MAT | 1,00,13,493 | 100% | | | | | | | M3 |
| S.No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | PTR(Rs.) | Brandwise MAT (Ignoring 0% MAT) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) |
| 1 | 23.2.1.3 | FLUOXETINE N6A8 | BETEALA 40 MG TABLET 10 | BETEALA | CNX HEALTHCARE PVT LTD | 40 MG | 10 | TABLET | 40.72 | 908137 | 9.07% | 9.07% | Y | 4.07 | 4.07 | | | | 4.07 |
| 2 | & 23.4.2 | FLUOXETINE N6A9 | CYCLOTIN 40 MG TABLET 15 | CYCLOTIN | ALTEUS BIOGENICS PVT.LTD. | 40 MG | 15 | TABLET | 61.25 | 1251093 | 12.49% | 12.49% | Y | 4.08 | 4.08 | | | | 4.08 |
| 3 | | FLUOXETINE N6A10 | F TIN 40 MG TABLET 10 | F TIN | A.N.PHARMACIA | 40 MG | 10 | TABLET | 42.8 | 1488456 | 14.86% | 14.86% | Y | 4.28 | 4.28 | | | | 4.28 |
| 4 | | FLUOXETINE N6A11 | FLOATIN 40 MG TABLET 10 | FLOATIN | ICON LIFESCENCES | 40 MG | 10 | TABLET | 47.1 | 5099687 | 50.93% | 50.93% | Y | 4.71 | 4.71 | | | | 4.71 |
| 5 | | FLUOXETINE N6A12 | FLOXIN (DD PHARMA) 40 MG TA | FLOXIN (DD P | D.D PHARMACEUTICALS | 40 MG | 10 | TABLET | 42.56 | 174624 | 1.74% | 1.74% | Y | 4.26 | 4.26 | | | | 4.26 |
| 6 | | FLUOXETINE N6A13 | FLUOXET 40 MG TABLET 10 | FLUOXET | SIGMUND PROMEDICA | 40 MG | 10 | TABLET | 42.43 | 424817 | 4.24% | 4.24% | Y | 4.24 | 4.24 | | | | 4.24 |
| 7 | | FLUOXETINE N6A14 | FLY 40 MG TABLET 10 | FLY | AGM BIOTEC | 40 MG | 10 | TABLET | 43.02 | 25681 | 0.26% | 0.26% | N | 4.30 | | | | | 4.30 |
| 8 | | FLUOXETINE N6A15 | S.R.B. 40 MG TABLET 10 | S.R.B. | ZEUS PHARMA | 40 MG | 10 | TABLET | 42.85 | 21596 | 0.22% | 0.22% | N | 4.29 | | | | | 4.29 |
| 9 | | FLUOXETINE N6A16 | THEOXETIN 40 MG TABLET 10 | THEOXETIN | THEO PHARMA PVT. LTD. | 40 MG | 10 | TABLET | 38.21 | 3362 | 0.03% | 0.03% | N | 3.82 | | | | | 3.82 |
| 10 | | FLUOXETINE N6A17 | TRITIN 40 MG TABLET 10 | TRITIN | TRIPADA HEALTHCARE PVT LTD | 40 MG | 10 | TABLET | 42.91 | 616039 | 6.15% | 6.15% | Y | 4.29 | 4.29 | | | | 4.29 |

| Computation of Ceiling Price based on July, 2022 Data under DPCO, 2013 | | | | | | | | | | | | | | | | | | | |
|--|------------------------|-------------------------|--|-------------|----------------------------|----------|-----------|--------|----------|---|------------------|---------------------------------|--------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| | | | | | | | | | | Number of Companies consisting of Market Share of 1% & Above | | | | | | | | | 8 |
| | 23.2.1.3 & 23.4.2 | Fluoxetine | Tablet 60 mg | | per Tablet | | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | | | | | | | 72.34 |
| | | | P,S,T | | | | | | | Sum of PTR per unit considered for price calculation | | | | | | | | | 50.77 |
| | | | | | | | | | | Number of Packs considered | | | | | | | | | 8 |
| | | | | | | | | | | Average PTR | | | | | | | | | 6.35 |
| | | | | | | | | | | Add : 16% Retailer Margin | | | | | | | | | 1.02 |
| | | | Ceiling Price w.e.f. 01.04.2022 | 9.21 | per Tablet | | | | | Ceiling Price (without GST) | | | | | | | | | 7.36 |
| | | | Maximum Permissible PT (S.O. 1573(E) dated 31.03.2023) | 7.94 | | | | | | % Reduction with compared to Highest Price | | | | | | | | | 10.49% |
| | | | | | | | | | | Final Ceiling Price (without GST) | | | | | | | | | 7.36 |
| | | | | | | | | | | Add: WPI Increase @ 12.1218% | | | | | | | | | 0.89 |
| | | | Ceiling Price | 8.22 | per Tablet | | | | | Ceiling Price (without GST) w.e.f. 01.04.2023 or date of notification, whichever is later | | | | | | | | | 8.25 |
| | | | Maximum Permissible PT (S.O. 1499(E) dated 30.03.2022) | 7.09 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | 5.90 |
| | | | | | | | | | | | | | | | | | | | 7.09 |
| | | | | | | | | | | | | | | | | | | | 6.35 |
| | | | | | | | | | | | | | | | | | | | 8.25 |
| | | | | | | | | | | | | | | | | | | | 10.40% |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | TOTAL MAT | 72,33,834 | 100% | | | | | | | M3 |
| S.No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | PTR(Rs.) | Brandwise MAT (Ignoring 0% MAT) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) |
| 1 | 23.2.1.3 | FLUOXETINE N6A8 | BETEALA 60 MG TABLET 10 | BETEALA | CNX HEALTHCARE PVT LTD | 60 MG | 10 | TABLET | 78.57 | 190296.54 | 2.63% | 2.63% | Y | 7.86 | 7.09 | | | | |
| 2 | & 23.4.2 | FLUOXETINE N6A9 | CYCLOTIN 60 MG TABLET 15 | CYCLOTIN | ALTEUS BIOGENICS PVT.LTD. | 60 MG | 15 | TABLET | 95.46 | 739719.54 | 10.23% | 10.23% | Y | 6.36 | 6.36 | | | | |
| 3 | | FLUOXETINE N6A10 | F TIN 60 MG TABLET 10 | F TIN | A.N.PHARMACIA | 60 MG | 10 | TABLET | 59.36 | 374502.24 | 5.18% | 5.18% | Y | 5.94 | 5.94 | | | | |
| 4 | | FLUOXETINE N6A11 | FLOATIN 60 MG TABLET 10 | FLOATIN | ICON LIFESCIENCES | 60 MG | 10 | TABLET | 65.78 | 3855386.36 | 53.30% | 53.30% | Y | 6.58 | 6.58 | | | | |
| 5 | | FLUOXETINE N6A12 | FLOXIN (DD PHARMA) 60 MG | FLOXIN (DD) | D.D PHARMACEUTICALS | 60 MG | 10 | TABLET | 59.04 | 242831.52 | 3.36% | 3.36% | Y | 5.90 | 5.90 | | | | |
| 6 | | FLUOXETINE N6A13 | FLUGEN (LA PHARMA) 60 MG | FLUGEN (LA) | LA PHARMACEUTICALS | 60 MG | 10 | TABLET | 82.08 | 101843.44 | 1.41% | 1.41% | Y | 8.21 | 7.09 | | | | |
| 7 | | FLUOXETINE N6A14 | FLUOXET 60 MG TABLET 10 | FLUOXET | SIGMUND PROMEDICA | 60 MG | 10 | TABLET | 59.14 | 96809.4 | 1.34% | 1.34% | Y | 5.91 | 5.91 | | | | |
| 8 | | FLUOXETINE N6A15 | TRITIN 60 MG TABLET 10 | TRITIN | TRIPADA HEALTHCARE PVT LTD | 60 MG | 10 | TABLET | 59.04 | 1632445.11 | 22.57% | 22.57% | Y | 5.90 | 5.90 | | | | |
| | | | Note: The PTR of item at S.N. 1 & 6 is higher than the Maximum Permissible PTR, therefore restricted to Maximum Permissible PTR. | | | | | | | | | | | | | | | | |

| Computation of Ceiling Price based on July, 2022 Data under DPCO, 2013 | | | | | | | | | | | | | | | | | | | |
|--|------------------------|-------------------------|--|--------------|--------------------------------|------------|-----------|--------|----------|---|--------------------|---------------------------------|--------------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| | | | | | | | | | | Number of Companies consisting of Market Share of 1% & Above | | | | | | | | | 7 |
| | 23.2.1.3 | Fluoxetine | Tablet 20 mg | | | per Tablet | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | | | | | | | 115.42 |
| | & 23.4.2 | | P,S,T | | | | | | | Sum of PTR per unit considered for price calculation | | | | | | | | | 22.35 |
| | & 7.4.6 | | | | | | | | | Number of Packs considered | | | | | | | | | 7 |
| | | | | | | | | | | Average PTR | | | | | | | | | 3.19 |
| | | | | | | | | | | Add : 16% Retailer Margin | | | | | | | | | 0.51 |
| | | | Ceiling Price w.e.f. 01.04.2022 | 4.93 | | per Tablet | | | | Ceiling Price (without GST) | | | | | | | | | 3.70 |
| | | | Maximum Permissible PT | 4.25 | | | | | | % Reduction with compared to Highest Price | | | | | | | | | 9.29% |
| | | | (S.O. 1573(E) dated 31.03.2023) | | | | | | | Final Ceiling Price (without GST) | | | | | | | | | 3.70 |
| | | | | | | | | | | Add: WPI Increase @ 12.1218% | | | | | | | | | 0.45 |
| | | | Ceiling Price | 4.40 | | per Tablet | | | | Ceiling Price (without GST) w.e.f. 01.04.2023 or date of notification, whichever is later | | | | | | | | | 4.15 |
| | | | Maximum Permissible PT | 3.79 | | | | | | | | | | | | | | | |
| | | | (S.O. 1499(E) dated 30.03.2022) | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | 2.87 |
| | | | | | | | | | | | | | | | | | | | 3.52 |
| | | | | | | | | | | | | | | | | | | | 3.19 |
| | | | | | | | | | | | | | | | | | | | 4.15 |
| | | | | | | | | | | | | | | | | | | | 15.85% |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | TOTAL MAT | 1,17,31,030 | 100% | | | | | | | M3 |
| S.No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | PTR(Rs.) | Brandwise MAT (Ignoring 0% MAT) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) | Price per Unit (Rs.) |
| 1 | 23.2.1.3 | FLUOXETINE N6A8 | ARKADEP 20 MG TABLET 10 | ARKADEP | RKG PHARMA | 20 MG | 10 | TABLET | 30 | 11370 | 0.10% | 0.10% | N | 3.00 | | | | | |
| 2 | & 23.4.2 | FLUOXETINE N6A8 | CYCLOTIN 20 MG TABLET 15 | CYCLOTIN | ALTEUS BIOGENICS PVT.LTD. | 20 MG | 15 | TABLET | 47.4 | 1447359 | 12.34% | 12.34% | Y | 3.16 | | | | | 3.16 |
| 3 | & 7.4.6 | FLUOXETINE N6A9 | EXITEN 20 MG TABLET 10 | EXITEN | SYNOKEM PHARMACEUTICALS LTD | 20 MG | 10 | TABLET | 29.72 | 16643 | 0.14% | 0.14% | N | 2.97 | | | | | |
| 4 | | FLUOXETINE N6A10 | F TIN 20 MG TABLET 10 | F TIN | A.N.PHARMACIA | 20 MG | 10 | TABLET | 35.2 | 2910298 | 24.81% | 24.81% | Y | 3.52 | | | | | 3.52 |
| 5 | | FLUOXETINE N6A11 | FASTGEN 20 MG TABLET 10 | FASTGEN | GENTECH HEALTCARE LTD | 20 MG | 10 | TABLET | 28.57 | 114 | 0.00% | 0.00% | N | 2.86 | | | | | |
| 6 | | FLUOXETINE N6A12 | FLAME 20 MG TABLET 10 | FLAME | SOLVATE LABORATORIES PVT LTD | 20 MG | 10 | TABLET | 29.64 | 230184 | 1.96% | 1.96% | Y | 2.96 | | | | | 2.96 |
| 7 | | FLUOXETINE N6A13 | FLOATIN 20 MG TABLET 10 | FLOATIN | ICON LIFESCIENCES | 20 MG | 10 | TABLET | 34.95 | 4144697 | 35.33% | 35.33% | Y | 3.50 | | | | | 3.50 |
| 8 | | FLUOXETINE N6A14 | FLOXIN (DD PHARMA) 20 MG TABLET 10 | FLOXIN (DD P | D.D PHARMACEUTICALS | 20 MG | 10 | TABLET | 31.6 | 120301 | 1.03% | 1.03% | Y | 3.16 | | | | | 3.16 |
| 9 | | FLUOXETINE N6A15 | FLUDEP (EAST WEST) 20 MG TABLET 10 | FLUDEP (EAS | EAST WEST PHARMA | 20 MG | 10 | TABLET | 29.92 | 25380 | 0.22% | 0.22% | N | 2.99 | | | | | |
| 10 | | FLUOXETINE N6A16 | LUXET 20 MG TABLET 10 | LUXET | ORGANIC LABORATORIES | 20 MG | 10 | TABLET | 29.95 | 12839 | 0.11% | 0.11% | N | 3.00 | | | | | |
| 11 | | FLUOXETINE N6A17 | MENTOL 20 MG TABLET 10 | MENTOL | MARC PHARMA | 20 MG | 10 | TABLET | 26.36 | 9806 | 0.08% | 0.08% | N | 2.64 | | | | | |
| 12 | | FLUOXETINE N6A18 | S.R.B. 20 MG TABLET 10 | S.R.B. | ZEUS PHARMA | 20 MG | 10 | TABLET | 29.55 | 57654 | 0.49% | 0.49% | N | 2.96 | | | | | |
| 13 | | FLUOXETINE N6A19 | THEOXETIN 20 MG TABLET 10 | THEOXETIN | THEO PHARMA PVT. LTD. | 20 MG | 10 | TABLET | 31.75 | 51172 | 0.44% | 0.44% | N | 3.18 | | | | | |
| 14 | | FLUOXETINE N6A20 | TRITIN 20 MG TABLET 10 | TRITIN | TRIPADA HEALTHCARE PVT LTD | 20 MG | 10 | TABLET | 31.76 | 2383034 | 20.31% | 20.31% | Y | 3.18 | | | | | 3.18 |
| 15 | | FLUOXETINE N6A21 | ZEXTO 20 MG TABLET 10 | ZEXTO | TRIKO PHARMACEUTICALS | 20 MG | 10 | TABLET | 28.71 | 306337 | 2.61% | 2.61% | Y | 2.87 | | | | | 2.87 |
| 16 | | FLUOXETINE N6A22 | ZOTIN (PRESCRIPTION) 20 MG TABLET 10 | ZOTIN (PRESC | PRESCRIPTION MEDICINES PVT LTD | 20 MG | 10 | TABLET | 33.64 | 3840 | 0.03% | 0.03% | N | 3.36 | | | | | |